GK01 stemness-enriched tumor-reactive T-cell therapy plus IL-2 in advanced solid tumors: ORR and clonal persistence results in a first-in-human phase I study (GUARDIAN-01). Phase 1 trial of a KRAS ...
New soft tissue sarcoma (STS) transcriptomic clusters to unveil STS subsets with unique biological characteristics and refine the accuracy of overall survival (OS) prediction. This is an ASCO Meeting ...
Membership of the Immune Oncology (IO) Program is comprised of a diverse and multidisciplinary group of investigators with robust strength in immunogenetics, cellular and molecular immunology, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results